Cel-Sci expands licensing agreement with Orient Europharma
The new agreement extends the Multikine collaboration to also cover South Korea, the Philippines, Australia and New Zealand. The licensing agreement initially focuses on the areas of head
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
The top-line results from the recently completed multi-center, randomized, double-blind, placebo-controlled Phase II trial indicated a statistically significant reduction in recurrences of C difficile associated diarrhea (CDAD) when
Approximately 36 patients were enrolled into this Phase II open-label, multi-center trial that is evaluating the efficacy and safety of CR011-vcMMAE 1.88mg/kg administered intravenously once every three weeks.